Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 191 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle arm Clear all
Completed Phase 3 Interventional Results available

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

NCT03168321
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, IDP-123 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
42
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • La Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

NCT05295732
View directory record Official record
Conditions
Ichthyosis
Interventions
TMB-001, Matching Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

NCT02367911
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
122-0551 Foam, Vehicle Foam
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • Ormond Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

NCT00098059
View directory record Official record
Conditions
Herpes Simplex
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 12 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 16, 2026, 4:15 AM EDT
Not listed Not applicable Interventional

EMDR vs. PC For Motor Vehicle Accident Trauma

NCT03271359
View directory record Official record
Conditions
Trauma, Psychological, Motor Vehicle Accident
Interventions
EMDR, PC
Behavioral
Lead sponsor
Trauma Institute & Child Trauma Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Northampton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

NCT01701024
View directory record Official record
Conditions
Acne
Interventions
ACYC, ACYC vehicle
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 16, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841
View directory record Official record
Conditions
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
Interventions
pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic

NCT01849991
View directory record Official record
Conditions
Gastrointestinal, Colic
Interventions
Lactobacillus reuteri, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Weeks to 3 Months
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

NCT05278624
View directory record Official record
Conditions
Rosacea
Interventions
Roflumilast Cream
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 16, 2026, 4:15 AM EDT
Terminated Not applicable Interventional

Improving the Appearance of Skin and Hair in Patients Undergoing Valley Fever Treatment

NCT03618992
View directory record Official record
Conditions
Valley Fever, Coccidioidomycosis
Interventions
Cholesterol-containing moisturizers
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 16, 2026, 4:15 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms

NCT07686198
View directory record Official record
Conditions
Photodamaged Skin
Interventions
Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy, Left Arm treated with vehicle serum and Intense Pulsed Light Therapy
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 16, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional

Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED

NCT05727878
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
KPI-012, KPI-012 Vehicle
Drug
Lead sponsor
Combangio, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Dothan, Alabama • Irvine, California • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

NCT06137157
View directory record Official record
Conditions
Netherton Syndrome
Interventions
ATR12-351
Drug
Lead sponsor
Azitra Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Palo Alto, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

NCT05078827
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

NCT00768690
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333, ketoconazole, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT01666210
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 16, 2026, 4:15 AM EDT
Not listed Phase 2 Interventional

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

NCT06225973
View directory record Official record
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug · Other
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 16, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

NCT05281809
View directory record Official record
Conditions
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Interventions
Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Drug
Lead sponsor
John Lister
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 16, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional Results available

DPCP for the Treatment of Alopecia Areata

NCT03651752
View directory record Official record
Conditions
Alopecia Areata
Interventions
Diphenylcyclopropenone (DPCP) Ointment
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

NCT02864082
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%
Drug
Lead sponsor
Patagonia Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 16, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)

NCT07816224
View directory record Official record
Conditions
Epiphora
Interventions
Atropine sulfate ophthalmic solution 0.005%, Vehicle arm
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne

NCT03709654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NB01, Vehicle Control
Biological · Other
Lead sponsor
Naked Biome, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • Arlington, Texas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 16, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 16, 2026, 4:15 AM EDT